Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies

Kristin G. Anderson; Ingunn M. Stromnes; Philip D. Greenberg

doi:10.1016/j.ccell.2017.02.008

Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies

Kristin G. Anderson, Ingunn M. Stromnes, Philip D. Greenberg

Microbiology

Research output: Contribution to journal › Review article › peer-review

382 Scopus citations

Abstract

T cell dysfunction in solid tumors results from multiple mechanisms. Altered signaling pathways in tumor cells help produce a suppressive tumor microenvironment enriched for inhibitory cells, posing a major obstacle for cancer immunity. Metabolic constraints to cell function and survival shape tumor progression and immune cell function. In the face of persistent antigen, chronic T cell receptor signaling drives T lymphocytes to a functionally exhausted state. Here we discuss how the tumor and its microenvironment influences T cell trafficking and function with a focus on melanoma, and pancreatic and ovarian cancer, and discuss how scientific advances may help overcome these hurdles.

Original language	English (US)
Pages (from-to)	311-325
Number of pages	15
Journal	Cancer Cell
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/j.ccell.2017.02.008
State	Published - Mar 13 2017

Bibliographical note

Funding Information:
Due to the broad scope of this perspective, we apologize for the omission of many primary references. This work was supported by the Chromosome Metabolism and Cancer Training Grant Program (T32 2T32CA009657-26A1 to K.G.A.), a Solid Tumor Translational Research Award (to K.G.A. and P.D.G.), an Irvington Institute Fellowship Program of the Cancer Research Institute (to I.M.S.), the Jack and Sylvia Paul Estate Fund to Support Collaborative Immunotherapy Research (to I.M.S.), the NIH National Cancer Institute (CA018029 and CA033084 to P.D.G.), the Pancreatic Cancer Action Network (16-65-GREE to P.D.G.). P.D.G. is a founder and shareholder of Juno, Therapeutics and a member of its scientific advisory board. This work was supported in part by a grant from Juno, Therapeutics.

Publisher Copyright:
© 2017 Elsevier Inc.

Keywords

T cell dysfunction
TME
adoptive T cell therapy
genetic engineering
immunotherapy
tumor microenvironment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.ccell.2017.02.008

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423788

Find It

Find It at U of M Libraries

Cite this

@article{6c7e8aa4e70a470e8265d8a4396a0c67,

title = "Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies",

abstract = "T cell dysfunction in solid tumors results from multiple mechanisms. Altered signaling pathways in tumor cells help produce a suppressive tumor microenvironment enriched for inhibitory cells, posing a major obstacle for cancer immunity. Metabolic constraints to cell function and survival shape tumor progression and immune cell function. In the face of persistent antigen, chronic T cell receptor signaling drives T lymphocytes to a functionally exhausted state. Here we discuss how the tumor and its microenvironment influences T cell trafficking and function with a focus on melanoma, and pancreatic and ovarian cancer, and discuss how scientific advances may help overcome these hurdles.",

keywords = "T cell dysfunction, TME, adoptive T cell therapy, genetic engineering, immunotherapy, tumor microenvironment",

author = "Anderson, {Kristin G.} and Stromnes, {Ingunn M.} and Greenberg, {Philip D.}",

note = "Funding Information: Due to the broad scope of this perspective, we apologize for the omission of many primary references. This work was supported by the Chromosome Metabolism and Cancer Training Grant Program (T32 2T32CA009657-26A1 to K.G.A.), a Solid Tumor Translational Research Award (to K.G.A. and P.D.G.), an Irvington Institute Fellowship Program of the Cancer Research Institute (to I.M.S.), the Jack and Sylvia Paul Estate Fund to Support Collaborative Immunotherapy Research (to I.M.S.), the NIH National Cancer Institute (CA018029 and CA033084 to P.D.G.), the Pancreatic Cancer Action Network (16-65-GREE to P.D.G.). P.D.G. is a founder and shareholder of Juno, Therapeutics and a member of its scientific advisory board. This work was supported in part by a grant from Juno, Therapeutics. Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = mar,

day = "13",

doi = "10.1016/j.ccell.2017.02.008",

language = "English (US)",

volume = "31",

pages = "311--325",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Obstacles Posed by the Tumor Microenvironment to T cell Activity

T2 - A Case for Synergistic Therapies

AU - Anderson, Kristin G.

AU - Stromnes, Ingunn M.

AU - Greenberg, Philip D.

N1 - Funding Information: Due to the broad scope of this perspective, we apologize for the omission of many primary references. This work was supported by the Chromosome Metabolism and Cancer Training Grant Program (T32 2T32CA009657-26A1 to K.G.A.), a Solid Tumor Translational Research Award (to K.G.A. and P.D.G.), an Irvington Institute Fellowship Program of the Cancer Research Institute (to I.M.S.), the Jack and Sylvia Paul Estate Fund to Support Collaborative Immunotherapy Research (to I.M.S.), the NIH National Cancer Institute (CA018029 and CA033084 to P.D.G.), the Pancreatic Cancer Action Network (16-65-GREE to P.D.G.). P.D.G. is a founder and shareholder of Juno, Therapeutics and a member of its scientific advisory board. This work was supported in part by a grant from Juno, Therapeutics. Publisher Copyright: © 2017 Elsevier Inc.

PY - 2017/3/13

Y1 - 2017/3/13

N2 - T cell dysfunction in solid tumors results from multiple mechanisms. Altered signaling pathways in tumor cells help produce a suppressive tumor microenvironment enriched for inhibitory cells, posing a major obstacle for cancer immunity. Metabolic constraints to cell function and survival shape tumor progression and immune cell function. In the face of persistent antigen, chronic T cell receptor signaling drives T lymphocytes to a functionally exhausted state. Here we discuss how the tumor and its microenvironment influences T cell trafficking and function with a focus on melanoma, and pancreatic and ovarian cancer, and discuss how scientific advances may help overcome these hurdles.

AB - T cell dysfunction in solid tumors results from multiple mechanisms. Altered signaling pathways in tumor cells help produce a suppressive tumor microenvironment enriched for inhibitory cells, posing a major obstacle for cancer immunity. Metabolic constraints to cell function and survival shape tumor progression and immune cell function. In the face of persistent antigen, chronic T cell receptor signaling drives T lymphocytes to a functionally exhausted state. Here we discuss how the tumor and its microenvironment influences T cell trafficking and function with a focus on melanoma, and pancreatic and ovarian cancer, and discuss how scientific advances may help overcome these hurdles.

KW - T cell dysfunction

KW - TME

KW - adoptive T cell therapy

KW - genetic engineering

KW - immunotherapy

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85015064348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015064348&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2017.02.008

DO - 10.1016/j.ccell.2017.02.008

M3 - Review article

C2 - 28292435

AN - SCOPUS:85015064348

SN - 1535-6108

VL - 31

SP - 311

EP - 325

JO - Cancer Cell

JF - Cancer Cell

IS - 3

ER -